H Lundbeck A/S (HLUN-B) - Total Liabilities
Based on the latest financial reports, H Lundbeck A/S (HLUN-B) has total liabilities worth Dkr29.11 Billion DKK (≈ $4.55 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
H Lundbeck A/S - Total Liabilities Trend (2004–2025)
This chart illustrates how H Lundbeck A/S's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
H Lundbeck A/S Competitors by Total Liabilities
The table below lists competitors of H Lundbeck A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PrairieSky Royalty Ltd
TO:PSK
|
Canada | CA$604.50 Million |
|
Floor & Decor Holdings Inc
NYSE:FND
|
USA | $3.16 Billion |
|
Arcosa Inc
NYSE:ACA
|
USA | $2.25 Billion |
|
Hong Leong Financial Group Bhd
KLSE:1082
|
Malaysia | RM309.77 Billion |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
USA | $7.11 Billion |
|
Landstar System Inc
NASDAQ:LSTR
|
USA | $840.27 Million |
|
Maha Properti Indonesia Tbk PT
JK:MPRO
|
Indonesia | Rp485.51 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down H Lundbeck A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how H Lundbeck A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for H Lundbeck A/S (2004–2025)
The table below shows the annual total liabilities of H Lundbeck A/S from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr29.11 Billion ≈ $4.55 Billion |
-8.94% |
| 2024-12-31 | Dkr31.97 Billion ≈ $5.00 Billion |
+108.08% |
| 2023-12-31 | Dkr15.36 Billion ≈ $2.40 Billion |
-7.86% |
| 2022-12-31 | Dkr16.67 Billion ≈ $2.61 Billion |
+1.83% |
| 2021-12-31 | Dkr16.37 Billion ≈ $2.56 Billion |
-14.07% |
| 2020-12-31 | Dkr19.06 Billion ≈ $2.98 Billion |
-10.13% |
| 2019-12-31 | Dkr21.20 Billion ≈ $3.32 Billion |
+142.04% |
| 2018-12-31 | Dkr8.76 Billion ≈ $1.37 Billion |
+15.64% |
| 2017-12-31 | Dkr7.58 Billion ≈ $1.19 Billion |
-27.97% |
| 2016-12-31 | Dkr10.52 Billion ≈ $1.65 Billion |
-16.14% |
| 2015-12-31 | Dkr12.54 Billion ≈ $1.96 Billion |
+3.54% |
| 2014-12-31 | Dkr12.11 Billion ≈ $1.89 Billion |
+19.11% |
| 2013-12-31 | Dkr10.17 Billion ≈ $1.59 Billion |
+21.55% |
| 2012-12-31 | Dkr8.37 Billion ≈ $1.31 Billion |
+7.82% |
| 2011-12-31 | Dkr7.76 Billion ≈ $1.21 Billion |
+12.71% |
| 2010-12-31 | Dkr6.88 Billion ≈ $1.08 Billion |
-17.31% |
| 2009-12-31 | Dkr8.32 Billion ≈ $1.30 Billion |
+65.99% |
| 2008-12-31 | Dkr5.01 Billion ≈ $784.60 Million |
-2.46% |
| 2007-12-31 | Dkr5.14 Billion ≈ $804.36 Million |
+5.65% |
| 2006-12-31 | Dkr4.87 Billion ≈ $761.35 Million |
+17.64% |
| 2005-12-31 | Dkr4.14 Billion ≈ $647.17 Million |
+12.71% |
| 2004-12-31 | Dkr3.67 Billion ≈ $574.18 Million |
-- |
About H Lundbeck A/S
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat maj… Read more